FDA to start new ‘precheck’ program to boost US drug production - biopharmadive.com
FDA is launching a new ‘precheck’ program aimed at enhancing US drug production efficiency.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. All pharmaceutical manufacturers, including branded drug makers, generic/ANDA manufacturers, and API & contract manufacturers. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Introduction of a new FDA program designed to streamline the drug production process.
Who it affects
All pharmaceutical manufacturers, including branded drug makers, generic/ANDA manufacturers, and API & contract manufacturers.
What you must do
Evaluate eligibility for the precheck program and prepare necessary documentation to participate.
Deadline
Not specified.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads - ajmc.com
- FDA to publish guidance to improve the Rx to OTC switch application process - Hogan Lovells Cadwalader
- FDA Issues Warning Letter for Refusal to Permit Inspection: Important Takeaways for Startups and Drug and Device Manufacturers - wsgr.com
- Michigan law shielding drug makers draws scrutiny amid opioid crisis - detroitnews.com
- Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court - kff.org